Bigfoot Biomedical has secured $57 million in financing as it works toward commercialising its diabetes management program.
According to a press release, Madryn Asset Management provided the financing to develop the Bigfoot Unity diabetes management program designed to simplify and connect aspects of insulin management to enable personalised, proactive and remote patient care.
The Bigfoot Unity program features smartpen caps that provide insulin dose decision support, allowing patients to follow doctors’ orders simply.
“As our company prepares for commercialisation of the Bigfoot Unity System, we are pleased to partner with Madryn, a firm with demonstrated success identifying transformative technologies within the healthcare industry,” Bigfoot CEO Jeffrey Brewer said. “Their investment will enable us to scale our commercial efforts with greater speed and geographic reach. Bigfoot’s deep and respected investor base reflects a strong validation of our commitment to developing breakthrough solutions in diabetes care.”